One-step treatment of periodontitis based on a core-shell micelle-in-nanofiber membrane with time-programmed drug release
One-step treatment of periodontitis based on a core-shell micelle-in-nanofiber membrane with time-programmed drug release
复制标题
基于纳米纤维膜核壳胶束定时药物释放的牙周炎一步治疗
DOI：
10.1016/j.jconrel.2020.01.045
复制
发表时间：
2020-04-10
影响因子：
10.8
通讯作者：
Huang, Chen
中科院分区：
文献类型：
--
作者：
Liu, Xiaochen;Zhang, Wenxin;Huang, Chen
牙周炎是一种慢性炎症性疾病，可导致牙槽骨吸收和不可逆的软组织损伤。然而，目前的治疗方法的疗效在很大程度上受到难以同时实现抗炎和骨再生的限制。同时，口腔内的动态环境容易使药物被吞咽或被唾液冲走。我们在这里报告一个一步处理的基础上的核壳结构的同轴静电纺丝膜制造。含有SP 600125的聚合物胶束分布在壳中，而BMP-2被掺入核中。交联后，聚乙烯膜显示出长达4周的降解和释放期。在开始时检测到SP 600125的释放，而BMP-2直到第12天才释放。这种时间程序化释放行为被证明是理想的抑制促炎因子的表达和增强成骨诱导在体外。进一步的体内研究证实，通过简单地用我们的牙周膜覆盖牙周炎部位，在很大程度上避免了牙槽骨破坏，骨缺损在2个月内恢复。综上所述，我们相信使用我们的膜与SP 600125和BMP-2的顺序释放可能成为牙周炎的一种方便和高度综合的治疗方法。
As a chronic inflammatory disease, periodontitis is responsible for irreversible soft tissue damage and severe alveolar bone resorption. However, curative effects of current therapies are largely confined by the difficulty to simultaneously achieve anti-inflammation and bone regeneration. Also, the dynamic environment in oral cavity easily causes the drugs swallowed or rinsed away by saliva. We report here a one-step treatment based on a core-shell nanofiber membrane fabricated by coaxial electrospinning. Polymeric micelles containing SP600125 were distributed in the shell, while BMP-2 was incorporated in the core. After crosslinking, the nanofiber membrane displayed a prolonged degradation and release period up to 4 weeks. The release of SP600125 was detected at beginning, whereas BMP-2 was not released until day 12. Such a time-programmed release behavior was proved desirable for suppressing the expression of pro-inflammatory factors and enhancing the osteogenic induction in vitro. Further in vivo investigation confirmed that, by simply covering the periodontitis site with our nanofiber membrane, alveolar destruction was largely avoided and bone defects recovered within 2 month. Taken together, we believe that the use of our membrane with sequential release of SP600125 and BMP-2 may become a convenient and highly comprehensive therapy for periodontitis.